Similar articles for PMID: 28771104

Year	Number of Results
2006	1
2013	4
2014	8
2015	5
2016	22
2017	26
2018	17
2019	11
2020	7
2021	5
2022	1
2023	1
2024	0

1

'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.

Gilham DE, Maher J. Gilham DE, et al. Immunotherapy. 2017 Aug;9(9):723-733. doi: 10.2217/imt-2017-0045. Epub 2017 Aug 3. Immunotherapy. 2017. PMID: 28771104 Review.

2

At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.

Daniyan AF, Brentjens RJ. Daniyan AF, et al. J Leukoc Biol. 2016 Dec;100(6):1255-1264. doi: 10.1189/jlb.5BT1215-556RR. Epub 2016 Oct 27. J Leukoc Biol. 2016. PMID: 27789538 Free PMC article. Review.

3

Versatile strategy for controlling the specificity and activity of engineered T cells.

Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y. Ma JS, et al. Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8. doi: 10.1073/pnas.1524193113. Epub 2016 Jan 12. Proc Natl Acad Sci U S A. 2016. PMID: 26759368 Free PMC article.

4

Exploiting natural killer group 2D receptors for CAR T-cell therapy.

Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S. Demoulin B, et al. Future Oncol. 2017 Aug;13(18):1593-1605. doi: 10.2217/fon-2017-0102. Epub 2017 Jun 14. Future Oncol. 2017. PMID: 28613086 Free article. Review.

5

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.

Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. Parihar R, et al. Cancer Immunol Res. 2019 Mar;7(3):363-375. doi: 10.1158/2326-6066.CIR-18-0572. Epub 2019 Jan 16. Cancer Immunol Res. 2019. PMID: 30651290 Free PMC article.

6

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J, Baumeister SHC. Driouk L, et al. Front Immunol. 2020 Dec 15;11:580328. doi: 10.3389/fimmu.2020.580328. eCollection 2020. Front Immunol. 2020. PMID: 33384686 Free PMC article.

7

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.

Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, Dranoff G, Fanger MW, Sentman CL. Sentman ML, et al. J Immunol. 2016 Dec 15;197(12):4674-4685. doi: 10.4049/jimmunol.1600769. Epub 2016 Nov 14. J Immunol. 2016. PMID: 27849169 Free PMC article.

8

NK-92 cell, another ideal carrier for chimeric antigen receptor.

Wang WN, Zhou GY, Zhang WL. Wang WN, et al. Immunotherapy. 2017 Aug;9(9):753-765. doi: 10.2217/imt-2017-0022. Epub 2017 Aug 3. Immunotherapy. 2017. PMID: 28771105 Review.

9

Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.

Marcus A, Eshhar Z. Marcus A, et al. Expert Opin Biol Ther. 2014 Jul;14(7):947-54. doi: 10.1517/14712598.2014.900540. Epub 2014 Mar 24. Expert Opin Biol Ther. 2014. PMID: 24661086 Review.

10

Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.

Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG, Kim CH, Young TS. Rodgers DT, et al. Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E459-68. doi: 10.1073/pnas.1524155113. Epub 2016 Jan 12. Proc Natl Acad Sci U S A. 2016. PMID: 26759369 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year